Weekly Research Analysts’ Ratings Updates for Latigo Biotherapeutics (LTGO)

A number of firms have modified their ratings and price targets on shares of Latigo Biotherapeutics (NASDAQ: LTGO) recently:

• 9/1/2026 – Latigo Biotherapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $50.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $73.00 price target on the stock.
• 8/15/2026 – Latigo Biotherapeutics was upgraded by Wall Street Zen to “hold”.

Insider Transactions at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, Director James B. Tananbaum purchased 140,000 shares of the stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. This represents a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.